MedinCell publishes its financial results and activity report for the first half of 2021-2022 (April – September 2021)

Revenue: €4.1 million (+30% compared with the first half of the previous year) 
Operating expenses: €15.3 million (+36%) 
Cash consumption from operations: €11.3 million 
Available cash: €34.4 million in cash + €3.0 million in non-risky financial assets (€2.9 million current + €0.1 million non-current) 
Post-closing (November 2021) €3.1 million received in Research Tax Credit + €3.0 million loan received from Bpifrance + €1.0 million, partially collected, as a grant within the framework of the French Recovery Plan (Plan France Relance)